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The 78-kDa glucose-regulated protein (Grp78) is stress-inducible chaperone that mostly 
reside in the endoplasmic reticulum. Grp78 has been described to be released at times 
of cellular stress and as having extracellular properties that are anti-inflammatory or favor 
the resolution of inflammation. As antigen-presenting cells (APCs) play a critical role in both 
the priming of adaptive immune responses and the induction of self-tolerance, herein, 
we investigated the effect of Grp78 on the maturation of murine myeloid APCs (CD11c+ 
cells). Results showed that CD11c+ cells could be bound by AF488-labeled Grp78 and 
that Grp78 treatment induced a tolerogenic phenotype comparable to immature cells. 
Furthermore, when exposed to lipopolysaccharide, Grp78-treated CD11c+ cells (DCGrp78) 
did not adopt a mature dendritic cell phenotype. DCGrp78-primed T cells exhibited 
reduced proliferation along with a concomitant expansion of CD4+CD25+FoxP3+ cells in 
pancreaticoduodenal lymph nodes and induction of T cell apoptosis in vitro and ex vivo. 
The above work suggests that Grp78 is an immunomodulatory molecule that could aid 
resolution of inflammation. It may thus contribute to induce durable tolerance to be of 
potential therapeutic benefit in transplanted allogeneic grafts and autoimmune diseases 
such as type I diabetes.
Keywords: glucose-regulated protein 78, antigen-presenting cells, regulatory T cell, immune regulation, 
autoimmune disease
inTrODUcTiOn
The endoplasmic reticulum (ER) chaperone Grp78/BiP is a central regulator of ER homeostasis, 
and its upregulation is widely used as a sentinel marker under pathologic conditions for ER stress, 
such as hypoxia, hypoglycemia, infection, nutrient deprivation, low-calcium, and others (1, 2). 
As an important cellular defense mechanism, Grp78 is highly increased in tumors and process 
to facilitate cell invasion, growth, and metastasis (3–6). Upregulation of Grp78 could lead to the 
translocation of Grp78 to other cellular locations and secretion of Grp78 into the extracellular 
compartment (7–11).
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Our previous work confirmed that overexpression of Grp78 
in insulinoma cells prolonged cell survival and subsequently 
maintained normoglycemia in diabetic Balb/c mice (12, 13). 
Interestingly, in the following experiments, it was found that 
Grp78-overexpressing insulinoma cell-treated animals secreted 
high levels of IL-4, suggesting the immunosuppressive ability of 
Grp78 in beta cell transplantation (13). However, it was not clear 
how Grp78 exerted such immunomodulatory effect for improve-
ment of alloimmunity.
Corrigall et  al. reported that recombinant human Grp78 
(rhGrp78) could prevent the induction of experimental arthritis 
when it was given i.v. before the induction of CIA (14) or during 
active disease to induce permanent remission of inflammation in 
CIA (15). At that time, they postulated that Grp78 just acted as an 
autoantigen to prevent the induction of arthritis. However, results 
suggested that Grp78 might have immunomodulatory properties 
because it appeared to be able to significantly suppress IgG2 
and IgG1 anti-collagen Abs. Later, they confirmed that rhGrp78 
affected the differentiation of human peripheral blood monocytes 
(PBMO) into dendritic cells (DCs) and reduced their expressions 
of HLA-DR and CD86, and thence the development of regulatory 
T cells (16). Furthermore, in 2011, Grp78 was proposed as one of 
the founding members of resolution-associated molecular pat-
terns (RAMPs) family that are anti-inflammatory and favor the 
resolution of inflammation (9).
We previously reported that recombinant mouse Grp78 
(rmGrp78) could program splenic B cells into CD19hiFasL+/
PD-L1+ IL-10-producing B cells to suppress T cell prolifera-
tion (17). Besides regulatory B cells, it is valuable to investigate 
whether Grp78 could program other murine antigen-present-
ing cells (APCs) into tolerogenic cells to prevent unwanted 
immune reactions in mice. In this study, we assessed the effect 
of rmGrp78 on DCs, which have a role in both the priming of 
adaptive immune responses and the induction of self-tolerance 
(18–20). Results showed that Grp78 could induce myeloid 
APCs (CD11c+ cells) to differentiate into a distinct tolerogenic 
cells, and these cells could retain tolerogenic signature after 
lipopolysaccharide (LPS) stimulation. DCGrp78-primed T cells 
exhibited reduced proliferation along with a concomitant 
expansion of Tregs and induction of T cell apoptosis in vitro and 
ex vivo. The above work suggests that Grp78 can contribute to 
induce durable tolerance to be of potential therapeutic benefit 
in transplanted allogeneic grafts and autoimmune diseases such 
as type I diabetes.
MaTerials anD MeThODs
Preparation of recombinant Murine grp78
Recombinant murine Grp78 was prepared as our previous report 
(17). Briefly, plasmid encoding full length of murine Grp78 
was transformed into Escherichia coli BL21 to generate Grp78. 
Protein was purified using GST Fusion Protein Purification Kit 
(GenScript, USA) and identified by SDS-PAGE and immunoblot-
ting. Endotoxins were removed by the Toxin Eraser™ Endotoxin 
Removal Kit (GenScript), and the endotoxin contamination 
was less than 1  EU/mg protein. The Grp78 concentration was 
detected by the BCA Protein Assay Kit (Beyotime, Beijing, 
China). Control extracts from empty vector-transformed E. coli 
BL21 were prepared in the same way.
animals
The female BALB/c mice (HFK Bioscience Co., Ltd., Beijing, 
China) used were between 6 and 8 weeks of age. Experiments were 
approved by the Ethics Committee of Tongji Medical College of 
Huazhong University of Science and Technology.
cell cultures
Bone marrow (BM)-derived CD11c+ cells from normal BALB/c 
mice were generated as described previously (21). Cells (80% 
purity, 90% viability) were harvested after 7 days of culture with 
10  ng/ml GM-CSF, 10  ng/ml IL-4, 10 μg/ml Grp78 or control 
extracts, and named as DCGrp78 or immature DC accordingly. 
LPS (500  ng/ml, Sigma, St. Louis, MO, USA) was added for 
the final 18–24  h to generate DCGrp78+LPS or DCLPS. Phenotypic 
characteristics were determined after 7 days of culture. Medium 
was replaced by fresh warmed medium with GM-CSF, IL-4, and 
Grp78. Cytokines and Grp78 were maintained at that concentra-
tion throughout medium changes.
Insulinoma cell line NIT (107) in the logarithmic growth phase 
were heated at 37°C for 30 min, washed in PBS, and subjected to 
four freeze (liquid nitrogen) and thaw (37°C water bath) cycles 
to obtain crude lysates. Prepared NIT lysates were added at 
100 μg/106 DCs and incubated overnight to obtain NIT lysate-
pulsed DCs.
CD4+CD25− T cells and CD8+ T cells were sorted by MACS 
(Miltenyi Biotec, Germany) from splenocytes. They were mixed 
with CD11c+ cells, respectively, in 96-well round-bottom plates 
with 0.3 μg/ml anti-CD3 molecular complex (BD) stimulation 
of T lymphocytes for 72 h. Proliferation of T cells was measured 
by CFSE (5–10  μM, Invitrogen) staining or incorporation of 
[methyl-3H]thymidine (1  μCi/well, BioCreater Co., Wuhan, 
China) for 6 h. Apoptosis was detected by 7-AAD staining. To 
analyze the differentiation of CD11c+ cells pulsed T cell, the 
mixed cells were transferred into 96-well flat-bottom plates for 
further 3-day culture.
identification of Binding of grp78 with 
cD11c+ cells
Grp78 was labeled with AF488 dye using Alexa Fluor® 488 Protein 
Labeling Kit (Invitrogen, Eugene, OR, USA) as per the manufac-
turer’s recommendation. Protein conjugates were purified using 
Protein Labeling Kit (Life Technologies, USA). BSA was labeled 
as a negative control. CD11c+ cells were harvested at different 
time (0/2/4/6 days after derived from BM) and cytospined and 
fixed with 4% paraformaldehyde and stained with Grp78-AF488 
at 4 or 37°C for 1  h. Confocal microscope (Olympus FV500, 
Tokyo, Japan) was used to visualize the binding of Grp78 with 
cells. Same amount of BSA-AF488 was used as negative control.
reagents for Flow cytometric analysis
The following fluorescein-labeled antibodies were used for cell 
surface marker analysis: CD11c-PE-cy7, CD40-APC, CD83-APC, 
CD80-PE-cy5, MHC-II-FITC, B7-H3-PE, B7-H4-PE, CD3-PE, 
CD8a-PE-Cy5, CD4-APC, CD25-PE-Cy7, and Foxp3-FITC. 
TaBle 1 | sequence of specific primers used.
name Primer sequence
GAPDH Sense: 5′-CCCCTTCATTGACCTCAACTAC-3′
Anti-sense: 5′-CTCGCTCCTGGAAGATGGTGAT-3′
IDO1 Sense: 5′-CTGCCTCCTATTCTGTCTTATGC-3′
Anti-sense: 5′-CTTTCAGGTCTTGACGCTCTACT-3′
Arg-1 Sense: 5′-GGGAAGACAGCAGAGGAGGTG-3′
Anti-sense: 5′-AGGTAGTCAGTCCCTGGCTTAT-3′
Cox-2 Sense: 5′-GATAACCGAGTCGTTCTGCCAAT-3′
Anti-sense: 5′-CCTGGTCGGTTTGATGTTACTG-3′
NOS2 Sense: 5′-CAGGGAATCTTGGAGCGAGTTG-3′
Anti-sense: 5′-GTGAGGGCTTGGCTGAGTGAG-3′
TGF-β1 Sense: 5′-GACCGCAACAACGCCATCTAT-3′
Anti-sense: 5′-GACAGCCACTCAGGCGTATCAG-3′
IFN-γ Sense: 5′-CTCTGAGACAATGAACGCTACAC-3′
Anti-sense: 5′-CCTTTTGCCAGTTCCTCCAGATAT-3′
TNF-α Sense: 5′-GCAGGTCTACTTTGGAGTCATTG-3′
Anti-sense: 5′-CAGGTCACTGTCCCAGCATCT-3′
IL-17A Sense: 5′-CCTCAGACTACCTCAACCGTTC-3′
Anti-sense: 5′-CTCTTCAGGACCAGGATCTCTT-3′
IL-4 Sense: 5′-GAGCCATATCCACGGATGCGAC-3′
Anti-sense: 5′-CGAAGCACCTTGGAAGCCCTAC-3′
IL-6 Sense: 5′-GACTTCCATCCAGTTGCCTTCT-3′
Anti-sense: 5′-TCTCATTTCCACGATTTCCCAG-3′
IL-10 Sense: 5′-GGACAACATACTGCTAACCGAC-3′
Anti-sense: 5′-CATGGCCTTGTAGACACCTTG-3′
IL-12a Sense: 5′-GGTCAGCGTTCCAACAGCCTC-3′
Anti-sense: 5′-ATGTGCTGGTTTGGTCCCGTGT-3′
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They were purchased for eBioscience (San Diego, CA, USA) 
except for CD83-APC from BioLegend (USA). For intracellular 
staining, Via-probe was added prior to fixation and permeabiliza-
tion. Data were acquired with flow cytometer and analyzed using 
FlowJo software.
cytokine analysis
ELISA kits were used for detection of IL-10, TGF-β, TNF-α, 
HMGB-1, and IFN-γ in cell culture supernatants (BOSTERBIO, 
Wuhan, China). Nitrite was measured as representative of NO 
synthesis in DCs’ culture supernatants using the Griess reagent 
(Sigma-Aldrich) and measuring absorbance at 540 nm.
relative Quantitative real-time Pcr
The total RNA was isolated from the CD11c+ cells using the 
Iso-plus reagent (TaKaRa, Dalian, China) according to the 
manufacturer’s protocol. cDNA was synthesized using M-MLV 
reverse transcriptase (TaKaRa). The real-time PCR reactions 
were performed in duplicate using a Light Cycler 480 PCR 
system (Roche, IN, USA) following the manufacturer’s instruc-
tions. Data were normalized using the geometric mean of 
housekeeping gene GAPDH. The primer sets were shown in 
Table 1.
Dc adoptive Transfer
MACS (Miltenyi Biotec) sorted CD11c+ DCs (5  ×  106) were 
injected intraperitoneally into 6- to 8-week-old BALB/c mice 
every 7 days for three times. Mice were sacrificed 1 week after 
final injection, and pancreaticoduodenal lymph nodes (PLNs), 
blood, and spleen were dissected.
statistical analysis
Statistical significance was determined by T-test, and percentage 
data were analyzed by Mann–Whitney U test using SPSS 17.0 
statistical software (SPSS Inc., USA). All values were expressed as 
means ±SD. A P value of < 0.05 was considered significant, and 
error bars were presented in SEM.
resUlTs
grp78 could Be Bound By cD11c+ cells
To investigate the effect of Grp78 on CD11c+ cells, it was essen-
tial to check whether Grp78 could be bound by cells. Confocal 
imaging studies showed that nearly all CD11c+ cells at 4- and 
6-day culture could be stained with Grp78-AF488, but none 
with BSA-AF488 (Figure 1). And the location of AF488-Grp78 
in cells showed no difference between 4 and 37°C. These figures 
confirmed the binding of Grp78 with CD11c+ cells.
grp78 induced an anti-inflammatory cell 
Phenotype
To assess the effect of Grp78 on modulation of CD11c+ cells, 
cells were cultured in the presence of Grp78 for 7 days and then 
subjected to phenotype analysis. Addition of Grp78 had down-
regulatory effects on the expression of MHC-II and DC matura-
tion markers CD83 on DCGrp78 cells compared with the immature 
cells (Figure 2A), diminishing their critical antigen presentation 
function. Among these molecules, MHC-II showed significant 
decrease not only in the mean intensity but also in the percentage 
in CD11c+ cells. Consistent with the downregulation of costimu-
latory molecules, DCGrp78 cells showed increased frequencies of 
B7-H3 and B7-H4 co-inhibitory molecules, but not B7-H1 and 
B7-DC (Figure 2B). Endocytosis is another important function 
for APCs during inflammation for clearance of both apoptotic 
cells and cellular debris from the local environment. The 
endocytic potential of CD11c+ cells was assessed by the uptake 
of dextran-rhodamine. However, DCGrp78 and immature DCs 
showed no evident differences in endocytic activity (Figure 2C). 
The resultant cytokine production (IL-10, TGF-β, NO, HMGB-1, 
IFN-γ) by DCGrp78 also did not alter when compared with imma-
ture cells (Figure 2D), as well as gene transcription phenotyping 
(Cox-2, ARG-1, iNOS, TGF-β, and TNF-α, Figure 2E).
As an example of tDC, immature DCs constitutively express 
low levels of costimulatory molecules and adhesion molecules, as 
well as weak antigen presentation capacity but strong endocytic 
activity (18). This is consistent with our studies. The findings of 
this DCGrp78 induction protocols indicated that Grp78 induced a 
specific tolerogenic cell phenotype comparable to immature DCs.
Dcgrp78 retained a Tolerogenic signature 
after Proinflammatory stimulation by lPs
During inflammation or infection, immature DCs undergo final 
maturation and become activated to induce immunity (16, 18), 
FigUre 1 | grp78 bound with cD11c+ cells. CD11c+ cells at different days of culture were cytospined for 1 min at 1000 rpm and then cocultured with 
AF488-labeled Grp78 (1 μmol/ml) at 4°C (a) or 37°C (B) for 1 h. Cell nuclei were stained with DAPI. Confocal microscope was used to check the Grp78+ cells. 
Same amount of AF488-BSA was used as a negative control.
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and no longer keep their tolerogenic properties. How to stabilize 
the immature DC phenotype is important for inducing tolerance 
in various autoimmune diseases. To assess the fate of DCGrp78 
phenotypes after proinflammatory stimulation, DCGrp78 cells were 
stimulated with LPS for 18–24 h. Results manifested that, upon 
LPS stimuli, DCGrp78 cells significantly expressed lower levels of 
MHC-II, CD83, CD86, and CD40 (Figure  3A). And, the fre-
quencies of B7-H3+/B7-H4+/B7-H1+ cells were not reduced and 
still significantly higher relative to DCLPS control (Figure 3B). 
Furthermore, DCGrp78+LPS cells retained their endocytic activity, 
but DCLPS cells lost this activity evidently (Figure 3C). In terms 
of cytokine secretion, DCGrp78 cells produced comparably higher 
levels of anti-inflammatory IL-10 and lower levels of proinflam-
matory TNF-α and NO when stimulated with LPS (Figure 3D). 
LPS is a strong inducer of cyclooxygenase (COX-2) (21), which 
is responsible for the elevated production of PGs during inflam-
matory processes. Our observations supported this result, and 
in agreement with tolerogenic signature of DCGrp78 cells, level 
of inducible form of COX-2 in these cells was not elevated and 
still significantly lower compared to DCLPS control (Figure 3E). 
These data indicated that DCGrp78 cells retained a tolerogenic 
signature and did not adopt a mature DC phenotype upon 
exposure to LPS.
grp78-Treated cD11c+ cells suppressed 
T-cell Proliferation In Vitro
Given the fact that a simple phenotypic determination of 
maturation markers does not guarantee a tolerogenic function 
and that a set of functional determinations is mandatory, an 
in vitro suppression assay was used, using anti-CD3 splenocyte 
activation, to clearly define tolerogenic functional phenotype 
of Grp78-treated cells. CD11c+ cells and CD4+CD25−, CD8+ 
T cells from splenocytes were enriched using Miltenyi MACS. 
The purity of all cell subsets was over 90% (Figure 4A). The fre-
quency of proliferating cells was determined by the percentage 
of CFSE dilution. Results showed that CD4+CD25−, CD8+ T cells 
cocultured with DCGrp78+LPS cells proliferated less than those 
with DCLPS cells (Figure 4B). These results indicated that Grp78 
had a role in the regulatory phenotype of CD11c+ cells to sup-
press T-cell proliferation. To elucidate the mechanism of their 
suppressive action, the ability of Grp78-treated cells to induce 
T cells’ apoptosis and to generate Tregs were assessed in vitro. 
FigUre 2 | grp78 induced a distinct anti-inflammatory phenotype.
(Continued)
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In accordance with CFSE proliferation assay, compared with 
immature DCs, DCGrp78 treatment increased the percentage of 
apoptotic T cells even at a low (1:16) DC:T titration. And, T cells 
cocultured with DCGrp78+LPS cells underwent more apoptosis than 
those with DCLPS (Figure 4C). The increment of apoptosis could 
result from the elevation of B7-H1 in DCGrp78 and DCGrp78+LPS 
FigUre 2 | continued  
Bone marrow cells (1 × 106) were costimulated for 7 days with IL-4, GM-CSF, and with/without Grp78. (a) Flow cytometry analyses of MHC-II, CD83, CD80, 
and CD40 expression on CD11c+ cells. Mean fluorescence intensity (upper), representative flow cytometric dot plots (middle), and percentage of positive cells 
(lower) were depicted. (B) Percentage of B7-H3/B7-H4/B7-1/B7-DC cells in CD11c+ cell population. (c) Endocytosis of CD11c+ cells assessed by 1 h 
incubation with dextran-rhodamine. MFI (left) and percentage of rhodamine positive cells (right) were depicted. (D) Cell culture supernatants were analyzed for 
IL-10, TGF-β, NO, HMGB-1, and IFN-γ by ELISA. (e) Gene expression of COX-2, TGF-β, TNF-α, iNOS, and ARG-1 assessed by qPCR. All results were 
representative of three independent experiments. Statistical comparisons were conducted against untreated controls. Error bars were presented in SEM. 
*P < 0.05 vs. DC, **P < 0.01 vs. DC.
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(Figures  2B and 3B). And, Grp78 pretreatment of DCLPS led 
to an increase in the percentage of CD4+CD25+FoxP3+ Tregs 
induced from CD25+-depleted CD4+ splenocytes (Figure 4D). 
Data meant that the regulation of T cell activities by Grp78-
treated DCs could result from increased T-cell deletion and 
expansion of Tregs.
grp78-Treated cD11c+ cells Kept its 
regulatory Function Ex Vivo
To address the local in  vivo mechanism of action of Grp78-
treated CD11c+ cells, BALB/c mice were injected with NIT 
lysate-pulsed CD11c+ cells for three times. PLNs, blood, and 
spleen were dissected out 1 week after final injection. Although 
the relative numbers (percentage of cells or absolute numbers) of 
CD4+ T cells and Treg (CD4+CD25+FoxP3+), Th1 (CD4+IFNγ+), 
Th2 (CD4+IL-4+), and Th17 (CD4+IL-17+) cells in blood or 
spleen did not alter among different CD11c+ cells treatment 
(Figures 5A–C), in PLNs, there was a statistical difference of fre-
quency of CD4+CD25+FoxP3+ Tregs in DCGrp78+LPS treated mice 
compared with DCLPS group (Figure 5A). When splenocytes were 
reprimed by NITs, antigen-specific proliferation was determined 
by CFSE dilution (Figure 5D) and 3H-TdR incorporation assay 
(Figure 5E). Splenocytes from DCGrp78+LPS treated mice prolifer-
ated less than those from DCLPS treated mice, clearly indicated 
immunomodulation of lymphocytes by Grp78-treated CD11c+ 
cells ex vivo. And, the immunomodulation may partly result from 
the increased apoptosis of lymphocytes in Grp78-DCs treated 
groups (Figure 5F).
DiscUssiOn
Dendritic cells exist in two basic functional states: immature 
DCs induce tolerance to self, whereas mature DCs induce 
immunity to foreign antigens. When receiving maturation 
signals in the form of microbial patterns, danger signals, or 
inflammatory cytokines, immature DCs lose their tolerogenic 
functions and transit to mature DCs that can prime T cells 
(18–20). Stabilization of the immature DC phenotype can con-
tribute to induce durable tolerance to transplanted allogeneic 
grafts and suppress the development of autoimmune diseases. 
FigUre 3 | grp78-treated cD11c+ cells retained a regulatory signature after proinflammatory stimulation by lPs in vitro.
(Continued)
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Attempts have been made in  vivo and in  vitro. For instances, 
IL-10 was used to modulated DCs from peripheral blood to 
induce antigen-specific anergy in CD4+ and CD8+ T cells (22). 
Immature DCs can also response to 1,25-dihydroxyvitamin D3, 
dexamethasone (23), and rapamycin (24) to be matured towards 
a Treg-inducing or tolerogenic state. Li et al. (25) even reported 
FigUre 3 | continued  
LPS was added for the final 18–24 h during cell culture to generate DCGrp78+LPS or DCLPS. (a) Flow cytometry analysis of MHC-II, CD83, CD80, and CD40 expression 
on DCGrp78+LPS and DCLPS cells. Mean fluorescence intensity and (upper), representative flow cytometric dot plots (middle), and percentage of positive cells (lower) 
were depicted. (B) Percentage of B7-H3/B7-H4/B7-H1/B7-DC cells in DCGrp78+LPS and DCLPS cells. (c) Endocytosis assessed by 1 h incubation with dextran-
rhodamine. MFI (left) and percentage of rhodamine positive cells (right) were depicted. (D) Cell culture supernatants were analyzed for IL-10, TGF-β, TNF-α, NO, 
HMGB-1, and IFN-γ by ELISA. (e) Gene expression of COX-2, TGF-β, TNF-α, iNOS, and ARG-1 assessed by qPCR. All results were representative of three 
independent experiments. Error bars were presented in SEM. *P < 0.05 vs. DCLPS, **P < 0.01 vs. DCLPS.
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that stimulation of DC with IFN-γ and CD40L resulted in rapid 
induction of IDO transcription and recapitulated the in  vivo 
switch from immunogenic to tolerogenic activity.
In this research, it was found that myeloid APCs could bind 
with recombinant murine Grp78, and in vitro phenotypic analy-
ses revealed that the Grp78 treatment induced a tolerogenic cell 
phenotype comparable to immature DCs. When assessing the 
fate of DCGrp78 phenotypes upon maturation signals, DCGrp78 cells 
were cultured in the presence or absence of LPS as a maturation 
stimulus, which have been shown that LPS-matured DCs acquire 
an enhanced ability to stimulate specific T cells and to block 
regulatory T-cell activity (26). Data indicated that after stimula-
tion by strong TLR4 ligand, DCGrp78 cells were comparatively 
resistant to maturation and did not adopt a mature DC phe-
notype. Among these phenotypic molecules, MHC-II showed 
significant decrease not only in DCGrp78 but also in DCGrp78+LPS. 
It  needs further investigation for how Grp78 signaling affects 
the expression of MHC-II.
Another functional property of tDCs is their decreased T cell-
stimulatory capability (27). The following in vitro cell prolifera-
tion assay manifested that Grp78-treated DCs had potentials for 
reducing T proliferations. It has been described that tDCs regulate 
T cell activities through several pathways, including clonal T cell 
depletion or exhaustion by a mechanism dependent on the 
induction of apoptosis, anergy, deviation of Th differentiation, or 
generation of Tregs (28, 29). To deduce which mechanisms that 
Grp78-treated myeloid APCs might have exerted, the possibility 
of apoptosis induction were evaluated. We did find significant 
differences in cell death by stimulated T cells, indicating that this 
mechanism was acting in our Grp78-treated cellular products. 
For the generation of Tregs, Grp78-DC-primed T cells exhibited 
reduced proliferation along with a concomitant expansion of 
CD4+CD25+FoxP3+cells. But, it is unclear whether CD11c+ cells 
only induce Treg or also contribute to the expansion of natural 
Treg. The in vitro immunomodulatory property of Grp78-treated 
CD11c+ cells was confirmed by ex  vivo T cell proliferation. 
Functional analyses revealed that these Grp78-treated CD11c+ 
cells could modulate the ex vivo antigen-specific activation of 
splenocytes. It can be suggested that in the proinflammatory envi-
ronment, the transferred Grp78-treated CD11c+ cells retained 
the tolerogenic signature and deactivated infiltrated T cells 
through induction of lymphocyte apoptosis and Treg formation. 
These anti-inflammatory effects may have been in response to the 
expression of low levels of CD86 and of high levels of co-inhibitory 
FigUre 4 | grp78-treated cells could suppress T-cell proliferation and induce formation of Tregs in vitro. (a) CD11c+ cells and CD4+CD25−, CD8+ T cells 
from splenocytes were isolated using Miltenyi MACS. The purity of CD11c+ cells (left), CD4+CD25− Teff (median), and CD8+ T (right) cells were tested. (B) CFSE-
stained T cells (2 × 105) were cocultured with αCD3 (0.3 μg/ml) and DCs at titration indicated, for 72 h. CFSE dilution of CD4+CD25− Teff (a) and CD8+ T cells (b) 
were analyzed. Proliferation index (left) and representative flow cytometric histograms (right) were depicted. (c) 7-AAD-stained CD4+CD25− Teff (left) and CD8+ 
T (right) cells were cocultured with CD11c+ cells, as described above. 7-AAD+ cells were analyzed. Percentage of apoptosis (upper) and representative images 
(lower) were depicted. (D) CD4+CD25− cells were cocultured with CD11c+ cells as described. Cells were gated for CD4+. CD25+FoxP3+ expressing cells were 
analyzed. Percentage of CD25+FoxP3+ cells (upper) and representative flow cytometric dot plots (lower) were depicted. The results were representative of three 
independent experiments. Statistical comparison was conducted as indicated. Error bars were presented in SEM. *P < 0.05, **P < 0.01.
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FigUre 5 | grp78-treated cD11c+ cells kept regulatory function ex vivo.
(Continued)
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molecules on Grp78-treated CD11c+ cells and is consistent with 
previous reports that CD28 costimulation negatively regulates 
the generation of Tregs (30) and B7-H3/B7-H4/B7-H1 are linked 
to limited T cell proliferation (31). Given the fact that during an 
immune response DCs can be exposed to a variety of stimuli in 
different combinations (32), future work need to be done to test 
FigUre 5 | continued  
NIT lysate-pulsed cells (5 × 106) were injected into 6- to 8-week-old BALB/c mice every 7 days for three times. Mice were sacrificed 1 week after final 
injection, and PLNs, blood, and spleen were dissected. Lymphocyte subsets from PLNs (a) and blood (B) were analyzed by flow cytometry for percent values. 
Cells were gated for CD3+. Percentage of CD4+ in CD3+ cells (left), percentage of CD25+FoxP3+ in CD4+ cells (median), and representative flow cytometric 
dot plots (right) were depicted. (c) Splenocytes were analyzed by flow cytometry for percent and absolute values. Frequencies and representative flow 
cytometric dot plots of Treg (CD4+CD25+FoxP3+), Th1 (CD4+IFNγ+), Th2 (CD4+IL-4+), and Th17 (CD4+IL-17+) cells were also indicated. (D,e) Splenocytes were 
reprimed with mitomycin-treated NITs for 5 days (D) or 3 days (e). Then, cell proliferation was assayed by CFSE dilution (D) or 3H-TdR incorporation (e). 
(F) Splenocytes were reprimed by mitomycin-treated NITs for 7 days and then subjected to CFSE staining. After coculture with NITs for 12 h, cell apoptosis in 
CFSE+CD3+ T cells was assayed. All results were representative of three independent experiments. Error bars are presented in SEM. *P < 0.05, **P < 0.01.
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whether DCGrp78 cells could retain tolerogenic signature once in 
the prolinflammatory environment, like CpG, TNF, IL-1β, IFNs, 
anti-CD40, and so on.
In regard to cytokine profile, Grp78-treated CD11c+ cells 
increased the production of IL-10, while showed no significant 
change for the expression of TGF-β. Zhang et al. (33) reported 
that GRP78 overexpression facilitated the expression and secre-
tion of TGF-β1 in colon cancer cells. This discrepancy could be 
due to the different cell types used and Grp78 functioning in 
different ways when it resides in different cell compartments.
A widely used protocol involves the culture of murine BM cells 
with GM-CSF to generate BMDCs. BMDCs express CD11c and 
MHC-II molecules and share with DCs isolated from tissues the 
ability to present exogenous antigens to T cells and to respond 
to microbial stimuli by undergoing maturation (34). GM-CSF 
plus IL-4 is a widely used protocol to culture murine BM cells 
to generate BMDCs (21, 35–37). CD11c+ cells obtained in this 
manner constitute pure DC populations although the cellular 
heterogeneity has been appreciated. In the paper, this protocol was 
applied to generate CD11c+ myeloid APCs. The purity of CD11c+ 
was over 80%. Helft et al. reported that mouse BM cultured in 
GM-CSF generates DCs and macrophages, which both express 
CD11c and MHC class II. IL-4 does not prevent the develop-
ment of monocyte-derived macrophages. And, the numbers of 
GM-CSF-macrophage needed to induce specific CTL response is 
10-fold higher than those of GM-CSF-DC (34). Hence, it is worth 
of our further studies to refine in vitro DC culture systems to gain 
a better understanding of the function of DCs and macrophages 
and has implications for the design of cell-based therapies for use 
in humans.
In summary, we verified that Grp78 regulates the maturation 
of myeloid APCs to produce a tolerogenic phenotype, and such 
phenotype is stable upon LPS stimulation. These Grp78-treated 
myeloid APCs could reduce T proliferations in a way that induce 
T cell apoptosis and generate Tregs in vitro and ex vivo. The above 
work supports that Grp78 is an immunomodulatory molecule. It 
may thus contribute to induce durable tolerance to be of poten-
tial therapeutic benefit in autoimmune diseases such as type I 
diabetes.
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